Joshua Higa
Vice President of Investor Relations
Replay available
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q1 2025 earnings conference call, held 2025-05-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Emil Kakas
Chief Executive Officer & President
Eric Harris
Chief Commercial Officer
Howard Horn
Chief Financial Officer
Eric Krambes
Chief Medical Officer
Yaron Werber
Analyst, TD Cowen
Kazin Amak
Analyst, Bank of America
Gina Wong
Analyst, Barclays
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ultragenyx Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.079 Good afternoon and welcome to the Ultragenyx First Quarter 2025 Financial 00:00:05.079 -- 00:00:10.469 Results Conference Call. At this time, all participants are in a listen-only mode. 00:00:10.469 -- 00:00:14.335 At the end of the prepared remarks, you will have an opportunity to ask questions during 00:00:14.335 -- 00:00:19.384 the Q&A portion of the call. It is now my pleasure to turn the call over to Joshua 00:00:19.384 -- 00:00:23.467 Higa, Vice President of Investor Relations. 00:00:23.971 -- 00:00:28.098 Thank you. We have issued a press release detailing our financial results, which you 00:00:28.098 -- 00:00:31.561 can find on our website at ultragenics.com. 00:00:31.561 -- 00:00:36.626 Joining me on this call are Emil Kakas, Chief Executive Officer and President, Eric Harris, 00:00:36.626 -- 00:00:41.911 Chief Commercial Officer, Howard Horn, Chief Financial Officer, and Eric Krambes, 00:00:41.911 -- 00:00:46.015 Chief Medical Officer. I'd like to remind everyone that during today's call, we will 00:00:46.015 -- 00:00:50.399 be making forward-looking statements. These statements are subject to certain risks and 00:00:50.399 -- 00:00:54.638 uncertainties, and our actual results may differ materially. 00:00:54.638 -- 00:00:58.483 Please refer to the risk factors discussed in our latest SEC filings. 00:00:58.483 -- 00:01:01.647 I'll now turn the call over to Emil. 00:01:01.647 -- 00:01:04.091 Thanks, Josh, and good afternoon, everyone. 00:01:04.091 -- 00:01:07.575 In the first quarter, we continued to make meaningful progress across one of the most 00:01:07.575 -- 00:01:11.721 productive commercial and development pipelines in rare diseases. 00:01:11.721 -- 00:01:14.985 Our commercial team delivered a strong quarter that put...